Search
Novo Nordisk Conducts Trials of Ozempic for Alzheimer's Disease Treatment, with Results Anticipated This Fall
2025-09-04 /
Read about 0 minute
Author：小编
Since its introduction seven years ago, Ozempic (semaglutide) has broadened the application of GLP-1 drugs beyond obesity and diabetes, encompassing heart disease, liver disease, and other medical areas. Now, Novo Nordisk is exploring its potential in treating Alzheimer's disease, with the anticipated announcement of trial results set for this fall.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
